adx-629
Small moleculeexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Jan 9, 2021 (NCT04728711)
Timeline
Indications
Mechanism of action
- reactive aldehydeMODULATOR
reactive aldehyde modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06685692 | Phase 2 | Nov 4, 2024 | Aldeyra Therapeutics, Inc. |
| NCT05717920 | Phase 2 | Feb 15, 2023 | Aldeyra Therapeutics, Inc. |
| NCT05443685 | Phase 1/Phase 2 (Phase 2) | Jan 2, 2023 | University of Nebraska |
| NCT05599815 | Phase 2 | Dec 31, 2022 | Aldeyra Therapeutics, Inc. |
| NCT05392192 | Phase 2 | Apr 7, 2022 | Aldeyra Therapeutics, Inc. |
| NCT05487404 | Phase 1/Phase 2 (Phase 2) | Nov 15, 2021 | Aldeyra Therapeutics, Inc. |
| NCT04908514 | Phase 2 | May 7, 2021 | Aldeyra Therapeutics, Inc. |
| NCT04847544 | Phase 2 | Mar 31, 2021 | Aldeyra Therapeutics, Inc. |
| NCT04728711 | Phase 2 | Jan 9, 2021 | Aldeyra Therapeutics, Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aldeyra Therapeutics, Inc. | For profit | 8 | 8 | 1 | 2021 |
| University of Nebraska | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1